



# Refractory Anaphylaxis: Data From the European Anaphylaxis Registry

Wojciech Francuzik<sup>1</sup>, Sabine Dölle-Bierke<sup>1</sup>, Macarena Knop<sup>2</sup>, Kathrin Scherer Hofmeier<sup>3</sup>, Ewa Cichocka-Jarosz<sup>4</sup>, Blanca E. García<sup>5</sup>, Roland Lang<sup>6</sup>, Ioana Maris<sup>7</sup>, Jean-Marie Renaudin<sup>8</sup> and Margitta Worm<sup>1\*</sup>

<sup>1</sup> Department of Dermatology, Venerology and Allergology, Charité—Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, Berlin Institute of Health, Berlin, Germany, <sup>2</sup> Department of Dermatology and Allergology, Klinikum der Universität München, Munich, Germany, <sup>3</sup> Department of Dermatology, University Hospital Basel, Basel, Switzerland, <sup>4</sup> Department of Pediatrics, Jagiellonian University Medical College, Kraków, Poland, <sup>5</sup> Service of Allergology, Complejo Hospitalario de Navarra, Pamplona, Spain, <sup>6</sup> Department of Dermatology, Paracelsus Private Medical University Salzburg, Salzburg, Austria, <sup>7</sup> Department of Paediatrics and Child Health, University College Cork, Cork, Ireland, <sup>8</sup> Réseau d'Allergo-Vigilance (Allergy Vigilance Network), Vandoeuvre les Nancy, France

## OPEN ACCESS

### Edited by:

Ulrich Blank,  
Institut National de la Santé et de la  
Recherche Médicale  
(INSERM), France

### Reviewed by:

Ilkka Harvima,  
University of Eastern Finland, Finland  
Eswari Dodagatta-Marri,  
University of California,  
San Francisco, United States

### \*Correspondence:

Margitta Worm  
margitta.worm@charite.de

### Specialty section:

This article was submitted to  
Molecular Innate Immunity,  
a section of the journal  
Frontiers in Immunology

**Received:** 21 November 2018

**Accepted:** 04 October 2019

**Published:** 18 October 2019

### Citation:

Francuzik W, Dölle-Bierke S, Knop M,  
Scherer Hofmeier K,  
Cichocka-Jarosz E, García BE,  
Lang R, Maris I, Renaudin J-M and  
Worm M (2019) Refractory  
Anaphylaxis: Data From the European  
Anaphylaxis Registry.  
Front. Immunol. 10:2482.  
doi: 10.3389/fimmu.2019.02482

Refractory anaphylaxis (unresponsive to treatment with at least two doses of minimum 300 µg adrenaline) is a rare and often fatal hypersensitivity reaction. Comprehensive data on its definition, prevalence, and risk factors are missing. Using the data from the European Anaphylaxis Registry (11,596 cases in total) we identified refractory anaphylaxis cases ( $n = 42$ ) and analyzed these in comparison to a control group of severe anaphylaxis cases ( $n = 4,820$ ). The data show that drugs more frequently elicited refractory anaphylaxis (50% of cases,  $p < 0.0001$ ) compared to other severe anaphylaxis cases (19.7%). Cases elicited by insects ( $n = 8$ ) were more often due to bees than wasps in refractory cases (62.5 vs. 19.4%,  $p = 0.009$ ). The refractory cases occurred mostly in a perioperative setting (45.2 vs. 9.05,  $p < 0.0001$ ). Intramuscular adrenaline (as a first line therapy) was administered in 16.7% of refractory cases, whereas in 83.3% of cases it was applied intravenously (significantly more often than in severe anaphylaxis cases: 12.3%,  $p < 0.0001$ ). Second line treatment options (e.g., vasopression with dopamine, methylene blue, glucagon) were not used at all for the treatment of refractory cases. The mortality rate in refractory anaphylaxis was significantly higher (26.2%) than in severe cases (0.353%,  $p < 0.0001$ ). Refractory anaphylaxis is associated with drug-induced anaphylaxis in particular if allergens are given intravenously. Although physicians frequently use adrenaline in cases of perioperative anaphylaxis, not all patients are responding to treatment. Whether a delay in recognition of anaphylaxis is responsible for the refractory case or whether these cases are due to an overflow with mast cell activating substances—requires further studies. Reasons for the low use of second-line medication (i.e., methylene blue or dopamine) in refractory cases are unknown, but their use might improve the outcome of severe refractory anaphylaxis cases.

**Keywords:** anaphylaxis, adrenaline (epinephrine), beta-blockers, insect venom allergy, drug allergic reactions, vasoconstriction, refractory

## INTRODUCTION

Anaphylaxis is a non-homogeneous clinical diagnosis, depending on various triggering and augmenting factors (1). This variability introduces a wide range of possible reaction-symptom severities. Therefore, multiple subtypes of anaphylaxis have been previously identified (i.e., food-dependent exercise-induced anaphylaxis, venom anaphylaxis, biphasic anaphylaxis).

The mainstay of anaphylaxis management is the intramuscular dose of adrenaline (2), but in the most severe cases of anaphylaxis, it might be insufficient to restore a stable patient status. Refractory anaphylaxis (although the established definition is lacking) might be defined as anaphylaxis meeting the criteria by NIAID/FAAN (3) which, after the treatment with at least two doses of minimum 300 µg adrenaline, does not achieve normalization of the clinical symptoms in a given individual. Common elicitors and symptoms of refractory anaphylaxis, as well as the therapeutic strategy for the most severe cases, differ from the usual reactions (4) and call for specific research and targeted guideline development for refractory anaphylaxis cases.

We aimed to distinguish the prevalence of refractory anaphylaxis among anaphylaxis cases and to describe symptoms and factors which may increase the risk of a refractory anaphylaxis episode.

## METHODS

The European Anaphylaxis Registry [described in detail elsewhere (5)] provided data for this analysis (status from March 2018). We selected cases where patients received at least two doses of adrenaline and failed to recover adequately and assigned them to the “refractory anaphylaxis group.” The flowchart in **Figure 1** represents the detailed case-selection process.

The final database consisted of 42 cases of refractory anaphylaxis from 7 countries: Germany: 19, Switzerland: 11, France: 6, Austria: 2, Poland: 2, Spain: 1, Ireland: 1. We compared these to a group of severe, non-refractory cases of anaphylaxis. Severe reactions were identified based on the definition by NIAID/FAAN (3) and presented with significant hypoxia, hypotension, confusion, collapse and loss of consciousness, or incontinence. We compared the frequency of various elicitors, symptoms, and factors known to increase the risk of severe anaphylaxis (6) in both groups as well as their management.

We performed a statistical analysis in the R Statistical Package (7). A simple comparison of categorical variables was performed using Fisher's exact test; continuous variables were analyzed using the Mann-Whitney *U*-test. We defined statistical significance as  $\alpha = 0.05$ . Data, along with the analysis script, can be accessed at [www.github.com/wolass/RefractoryAnaOrg](http://www.github.com/wolass/RefractoryAnaOrg).

## RESULTS

### Refractory Anaphylaxis Accounts for Less Than 0.5% of Severe Anaphylaxis Cases in the Register

The European Anaphylaxis Registry captured 42 cases of refractory anaphylaxis and 4,820 severe, non-refractory

anaphylaxis. The frequency of refractory anaphylaxis was 0.37% of all anaphylaxis cases reported in the registry. Each year  $\sim 1\%$  ( $0.853\% \pm 0.765\%$ ) of severe anaphylactic episodes are refractory to treatment with adrenaline. When considering patients who experienced anaphylaxis in a perioperative setting or a medical facility, nearly 3.72% patients present with reactions that do not respond to adrenaline vs. 0.448% in non-medical setting (9.3 times more).

### Increased Frequency of Previous Reactions in Patients With Refractory Anaphylaxis

The mean age at the reaction was  $41.4 \pm 20.8$  years, which did not differ from severe, non-refractory cases,  $p = 0.897$ . The percentage of males within the refractory anaphylaxis group was 50%. More patients suffered from a concomitant malignant disease in the refractory anaphylaxis group. Most strikingly, patients with refractory reactions more often had a previous anaphylactic reaction in their medical history ( $p = 0.0336$ ). Baseline tryptase levels were significantly higher in the refractory anaphylaxis group as 7 refractory patients (16.7%) had tryptase level above 11.5 µg/L (vs. 7.8%). The demographic summary of refractory cases is shown in **Table 1**.


### Drugs Are the Most Frequent Elicitors of Refractory Anaphylaxis

Refractory anaphylaxis was most commonly elicited by drugs (significantly more often than in severe, non-refractory cases), followed by food and insects (**Table 2**). The most common drugs eliciting anaphylaxis refractory to adrenaline were antibiotics (19%) and radiocontrast media (RCM, 7.14%). Patients with refractory anaphylaxis more frequently experienced the reaction while undergoing a medical procedure (54.8% vs. 12.3 in severe, non-refractory cases,  $p < 0.0001$ ).

Thirty three percent of food elicited refractory cases had a previously confirmed diagnosis of food allergy. Insect-venom and food allergens most frequently elicited severe cases of anaphylaxis. Refractory anaphylaxis cases were more often elicited by bees than severe, non-refractory cases,  $p = 0.0092$  (**Table 3**).

### Refractory Anaphylaxis Is Life-Threatening

Milder anaphylaxis symptoms (i.e., pruritus, gastrointestinal symptoms, vertigo, chest, and throat tightness) were significantly less present in refractory anaphylaxis cases, whereas respiratory and cardiac arrest, as well as inspiratory and expiratory distress, and death were more often associated with the refractory anaphylaxis cases. **Table 4** summarizes the most prominent differences in anaphylaxis symptoms among both groups. Fatal reactions frequently occurred 30–120 min after allergen exposure and were highly associated with refractory cases (26.2% vs. only 0.353% of severe anaphylaxis cases,  $p < 0.0001$ ). In cases where patients responded to life support, but failed to be reanimated due to post-resuscitative complication (e.g., hypoxic brain injury), death occurred in the next 3–8 days.



**FIGURE 1 |** Flowchart illustrating the cases selection process for the final database.

### Adrenaline i.v. as First-Line Treatment Was Given Frequently in Refractory Anaphylaxis

When evaluating the therapeutic procedures, adrenaline i.v. as a first-line treatment of anaphylaxis was significantly more often given in refractory cases (83.3% vs. 16.7%,  $p < 0.0001$ ). Median time to the second dose of adrenaline was also shorter in refractory cases (2 vs. 15 min in non-refractory cases,  $p < 0.0001$ ).

Corticosteroids i.v. were the second most frequently administered group of drugs in refractory cases (as a first and

second-line treatment), outpacing antihistaminic drugs, and volume replacement therapy, and were significantly more often given in refractory cases. Volume replacement therapy was given initially in 61.9% of refractory cases and was sustained only in 19% as the therapy progressed in the hospital environment.

Second-line medication like dopamine, glucagon, and methylene blue were not given in all refractory anaphylaxis cases as well as in severe non-refractory ones. However, patients with refractory anaphylaxis were more frequently admitted to

**TABLE 1** | Summary of the refractory anaphylaxis cases.

Sex	Group	n	Age	Cardiologic	DM	Food allergy	Mastocytosis	Malignancy	Atopic dermatitis	Tryptase [median]
Female	Refractory	22	40.0	31.82	9.09	13.64	9.09	0.00	18.18	5.22
Male	Refractory	20	43.0	30.00	15.00	5.00	5.00	15.00	5.00	7.43
Female	Severe	2421	43.4	20.57	2.27	5.37	2.56	2.19	6.73	4.30
Male	Severe	2399	40.2	22.89	3.58	5.84	2.54	2.08	6.25	4.72
	p-value	0.78	0.9	0.19	0.07	1.00	0.10	0.07	0.20	0.01

Age is represented by a mean value, other variables as fractions [%]. DM, diabetes mellitus, p-value is derived from a Mann-Whitney U-test or a  $\chi^2$  test for interval and categorical variables, respectively. Refractory group was compared to severe anaphylaxis cases without differentiating into male and female subgroups.

**TABLE 2** | Summary of elicitors in the refractory anaphylaxis cases and severe, non-refractory anaphylaxis cases as a control.

Elicitor	n	%	% severe ANA	Perioperative [n]	Food allergy [n]	Age	Male [%]	p
Food	9	21.4	24.1	0	3	17.4	55.6	0.8560
Drugs	21	50.0	19.7	19	0	48.8	42.9	0.0001
Insects	8	19.0	48.1	0	0	46.5	62.5	0.0001
Other	2	4.8	3.0	0	1	38.0	0.0	0.3610
Unknown	2	4.8	5.1	0	0	55.5	50.0	0.0001

ANA, anaphylaxis, age is represented as a mean, p-value derived from the Fisher's exact test.

**TABLE 3** | Comparison of the specific elicitors from each elicitor-group between the refractory anaphylaxis cases and severe anaphylaxis cases as a control.

Elicitor	Severe ANA [%]	Refractory ANA [%]	p-value
Antibiotics	6.140	19.00	0.0040
X-ray medium	0.954	7.14	0.0080
Muscle relaxant	0.456	4.76	0.0180
Legumes	4.020	7.14	0.2410
Bee venom	9.320	11.90	0.5890
Yellow-jacket venom	33.300	4.76	0.0001

ANA, anaphylaxis, p-value derived from the Fisher's exact test.

the hospital (85.7%) and treated at the ICUs (78.6%). **Table 5** illustrates the therapy of refractory anaphylaxis cases.

## Cofactors of Refractory Anaphylaxis

Patients with refractory anaphylaxis more often had concomitant asthma and malignant diseases in their medical history. Also, other unspecified concomitant conditions were significantly more often reported in refractory cases. Concomitant cardiologic conditions, diabetes, and mastocytosis were similarly frequent in both groups.

Patients with refractory anaphylaxis more often reported concomitant intake of proton pump inhibitors (PPI) and acetylsalicylic acid (ASA) compared with patients with severe non-refractory anaphylaxis. Other (not specified) medications were also more frequent in refractory cases. In 6 cases of refractory anaphylaxis (14.3%) patients reported receiving beta-blockers as a concomitant medication, but none of these patients received a glucagon infusion.

**TABLE 4** | Summary of the symptoms in the refractory anaphylaxis cases and severe, non-refractory anaphylaxis cases as a control.

Symptom	Severe ANA [%]	Refractory ANA [%]	p-value
Pruritus	45.40	23.80	0.0050
Skin symptoms	44.80	26.20	0.0190
Respiratory symptoms	62.10	81.00	0.0150
Respiratory arrest	3.03	28.60	0.0001
Chest tightness	8.90	2.38	0.1760
Throat tightness	14.60	7.14	0.2680
Expiratory distress	5.08	26.20	0.0001
Inspiratory stridor	5.31	19.00	0.0020
Loss of consciousness	31.90	40.50	0.2470
Cardiac arrhythmia	3.30	11.90	0.0130
Cardiac arrest	3.07	42.90	0.0001
Vertigo	38.70	14.30	0.0001
Death	0.35	26.20	0.0001

ANA, anaphylaxis, p-value derived from the Fisher's exact test.

The intensity of physical exercise exceeding the reaction was indifferent between groups, however psychological burden (defined as a stressful event preceding the reaction, rated by the physician) was reported three times more frequently in refractory cases (see **Table 6**).

## DISCUSSION

### Frequency of Refractory Anaphylaxis and Patients at Risk

Our findings suggest that around 1 in 100 severe anaphylaxis patients will not respond to the standard therapy with adrenaline,

**TABLE 5 |** Summary of therapeutic measures in the refractory anaphylaxis cases and severe, non-refractory anaphylaxis cases as a control.

Therapy	Severe ANA [%]	Refractory ANA [%]	p-value
Adrenaline i.m.	8.38	16.70	0.0840
Adrenaline i.v.	12.30	83.30	0.0001
Adrenaline i.v. 2nd line	0.73	40.50	0.0001
Volume	20.50	61.90	0.0001
Volume, 2nd line	3.34	19.00	0.0001
Antihistaminics i.v.	40.90	64.30	0.0030
Antihistaminics i.v. 2nd line	3.84	21.40	0.0001
Corticosteroids, all routes	5.52	7.14	0.5040
Corticosteroids i.v.	48.80	73.80	0.0020
Corticosteroids i.v. 2nd line	5.37	28.60	0.0001
Beta-2-mimetics i.v.	0.66	2.38	0.2500
Beta-2-mimetics inh. 2nd line	0.75	7.14	0.0040
Theophylline i.v.	0.42	0.00	1.0000
100% oxygen	9.42	47.60	0.0001
Dopamine i.v.	0.04	0.00	1.0000
Glucagon i.v.	0.02	0.00	1.0000
Methylene blue	0.00	0.00	1.0000
Hospital admission	28.00	85.70	0.0001
Intensive care	7.55	78.60	0.0001

"2nd line" refers to the therapy performed by the professional medical emergency team after the initial rescue procedures. ANA, anaphylaxis, p-value derived from the Fisher's exact test.

commonly outlined in anaphylaxis management guidelines (8). Such cases have the highest risk of a fatal outcome, and therefore need to be treated accordingly. Early use of adrenaline and maybe other second-line drugs (e.g., methylene blue and dopamine) might increase their survival chance.

Overall, the severity of anaphylaxis and its probable transition into a refractory episode might depend on several co-influencing mechanisms: (1) elicitors—the type and dose of an eliciting agent and route of exposure; (2) cofactors—the presence of other individual and external factors which may increase the severity of a given reaction, e.g., concomitant use of a beta-blocker; (3) compensation—how well the affected individual can compensate reaction symptoms, e.g., hypotension; (4) therapy—how fast and accurately the therapeutic interventions were applied (**Figure 2**).

## Elicitors

Drugs were the most commonly occurring elicitor, which is in concordance with the literature and our previous findings (4). Multiple medications with mast cell activation potential (9) given in a perioperative setting increase the chance of a hypersensitivity reaction and drug interactions (10). A recent study on IgE-independent anaphylaxis showed that perioperative drugs (i.e., rocuronium, tubocurarine, fluoroquinolones, atracurium) might trigger anaphylaxis by activating mast cells directly through the MRGPRX2 receptor (11). Therefore, patients undergoing surgical procedures and having a history of anaphylaxis should remain under extraordinary caution.

**TABLE 6 |** Factors potentially increasing the risk of a severe anaphylaxis investigated in refractory cases.

Factor	Severe ANA [%]	Refractory ANA [%]	p-value
Concomitant asthma	12.10	29.30	0.0030
Concomitant AD	6.82	12.20	0.2000
Concomitant diabetes	5.80	13.20	0.0700
Concomitant cardiologic condition	22.80	31.70	0.1910
Concomitant infection	3.35	4.88	0.6480
History of malignant disease	3.12	10.80	0.0290
Concomitant mastocytosis	2.68	7.32	0.0990
Concomitant other disease—unspecified	15.60	36.60	0.0001
Exercise prior to reaction	28.10	21.40	0.3920
Psychological burden	6.79	26.20	0.0001
Concomitant medication	37.50	60.50	0.0060
ASA	6.13	18.40	0.0080
Beta-blockers	10.40	15.80	0.2810
PPI	5.81	20.60	0.0030
Other drugs	18.20	44.70	0.0001
Alcohol use prior to the reaction	5.51	2.63	0.7210

ANA, anaphylaxis, p-value derived from the Fisher's exact test.


Antibiotics, although commonly triggering IgE-dependent reactions (12), are rarely reported in the literature as the cause of refractory anaphylaxis. RCM, on the other hand, commonly elicit IgE-independent hypersensitivity episodes that are refractory to adrenaline and are responsible for 1–5 deaths per 100,000 administrations (13). We previously reported RCM to be the most frequent elicitor of refractory anaphylaxis (4). It might be that RCM promotes complement activation (14) and thus—unspecific activation of multiple immune cell classes (mast cells, basophils, platelets, and neutrophils). Therefore, treatment with adrenaline may be less effective in these reactions.

Yellow-jacket-stings elicited only a few refractory cases. Therefore, the ratio of yellow-jacket to honey-bee venom elicited anaphylaxis was inverted in the refractory group. Reasons for this observation might include higher allergen exposition due to either extended exposition to the allergen (bee's sting remains in the skin) or the venom volume being 10 times higher than in a wasp sting (15).

## Risk Factors

Although we have previously identified higher age and male sex to be associated with severe anaphylaxis (6), these factors seem to be less critical in refractory anaphylaxis cases. By contrast, we previously associated concomitant asthma with less severe anaphylaxis in our registry data (6). However, the present analysis, as well as other previous data (16), suggest concomitant asthma as a risk factor for a severe episode. Probably the control of the asthmatic condition is essential in this context and should be therefore evaluated in patients at risk. Moreover, it might be possible that during a refractory episode the bronchospasm is additionally triggered via mediators derived from basophils and eosinophils or the vegetative nerve system what makes it





**FIGURE 2** | Visual representation of the three forces determining the severity of anaphylaxis. The natural ability of the body to compensate for the anaphylaxis symptoms and therapeutic measures acting to restore homeostasis. Elicitors and cofactors influence the severity of a given episode synergistically.

refractory to adrenaline and results in a prolonged anaphylactic episode. Accordingly, we observed more respiratory distress symptoms in the refractory anaphylaxis cases.

Baseline serum tryptase (BST) levels were increased in patients with refractory anaphylaxis, although only in 7 patients they exceeded the threshold level of 11.5 ng/mL—what is commonly recognized as elevated (17). BST may reflect pro- $\beta$  tryptase due to increased body mast cell content (18) or result from alpha-tryptasemia due to multiple copies of *TPSAB1* gene (19). Irrespective of the mechanism—increased BST has been shown to correlate with the severity of anaphylaxis (20).

The higher rate of malignancy in patients with refractory anaphylaxis diseases might be a confounder as certain intravenous chemotherapeutics are well known to directly activate mast cells (e.g., taxanes) (21). On the other hand, it is possible that patients with reported malignancies were older (mean age of 34.6 vs. 58.3 years,  $p < 0.001$ ) and therefore less able to compensate the anaphylactic shock.

Psychological stress in temporal proximity to the reaction might increase the severity of the reaction as we previously reported (6). Stress induces the complement cascade activation (22). Substance P, released during stress (23), is a known vasodilator (24) and can activate mast cells directly (25). These mediators may contribute to an increased mast cell response and more severe anaphylaxis. Some published case reports indicated stressful event as the anaphylaxis trigger (26).

Wölbling et al. indicated the role of PPI as a risk factor for severe anaphylaxis by prolonging the exposition to an oral allergen (preventing its degradation due to lower gastric acid production) (27). Moreover, there are reports on PPI themselves as elicitors of anaphylaxis (28). We observed a significantly higher rate of PPI intake in the refractory anaphylaxis group. Its mechanistic contribution to the increase in severity of an episode or being responsible for its refractoriness cannot be estimated based on this observation.

Concomitant ASA use was also associated with refractory cases more frequently than in severe anaphylaxis. The role of ASA on increasing the severity of anaphylaxis has previously been implicated by increasing the intestinal absorption of allergens (27). Nevertheless, as ASA might be both a cofactor and elicitor of anaphylaxis (29) and is highly correlated with another cofactor—concomitant cardiologic conditions—it is tough to evaluate its isolated influence on the anaphylaxis severity.

### Symptom Compensation

Age is the most critical factor influencing the risk of developing severe anaphylaxis (6). We and others have shown that older age may correlate with the decreased ability to retain homeostasis on increased strain (30). Patients who underwent refractory anaphylaxis more often had perioperative reactions and therefore, a decreased ability to compensate the reaction symptoms with reflexive renal or cardiopulmonary response (31).

Compensation mechanisms demonstrated in animal models indicated that anaphylactic hypotension activates the hypothalamic paraventricular nucleus, medullary nucleus tractus solitarius, and rostral ventrolateral medulla, independently of the baroreflex pathway. Further, it stimulates efferent sympathetic nerve activity to the adrenal gland and kidney to restore blood pressure (32).

## Therapy

Physicians and surgeons often used adrenaline i.v. as first-line therapy in refractory cases, probably because most of them occurred in a medical setting. However, other second-line therapeutic options were rarely used. Grabenhenrich et al. (2) recently evaluated the epinephrine usage in anaphylaxis patients and concluded that, even in this state of the art drug, significant discrepancies between recommended use and actual treatment practice exist. Similarly, US studies documented poor adherence in patients and caregivers to anaphylaxis guidelines recommending more than one adrenaline autoinjector available at all times (33). Therefore, more effort needs to be dedicated to promote and develop consensus guidelines as practically as possible in order to increase adherence.

Methylene blue and vasopressors have been described to successfully restore refractory hypotension and recommended by management guidelines (8), but their actual use in anaphylaxis patients is scarce. There are multiple reports of successful methylene blue use in refractory anaphylaxis (4). Evora (34) reported 6 cases of refractory, perioperative anaphylaxis (to RCM and penicillin) which responded to methylene blue i.v. within minutes. Methylene blue blocks the guanylate cyclase and therefore prevents further nitric-oxide-dependent vasodilation in a distributive shock (35). Its potential role in neuroprotection has also been indicated (36).

Surprisingly, even though multiple anaphylaxis management guidelines recommend glucagon infusions in cases of concomitant beta-blocker therapy in anaphylactic patients (8, 37, 38), it has not been administered in any of the severe or refractory cases. Similarly, Royal College of Anesthetists reported one glucagon administration in 266 severe intraoperative anaphylaxis episodes (39). Glucagon has been reported to successfully relieve refractory anaphylaxis (40, 41) by directly activating the adenylyl cyclase and therefore bypassing the  $\beta$ -adrenergic receptor blockade (40).

## Limitations and Strengths

The low number of refractory cases prevented us from analyzing the data with more advanced statistical models. However, our analysis is the first report on a patient cohort exceeding 30 refractory anaphylaxis cases.

The definition of refractory anaphylaxis is not universal, and we had to assume it based on the answers to our online questionnaire. If a fatal reaction occurred before the second dose of adrenaline was administered to the patient (although, it might have been refractory)—it was not categorized as refractory as we defined at least two doses of minimum 300  $\mu$ g adrenaline for refractory anaphylaxis.

The therapy with adrenaline was not weight-adapted, and patients received multiple fixed doses of adrenaline ranging from 300 to 1,000  $\mu$ g. It is possible that patients experiencing anaphylaxis refractory to standard doses of adrenaline were treated with subtherapeutic doses in the initial phase of the reaction due to their obesity. However, we did not gather data on the patient's weight, and therefore, we cannot conclude how it influenced the therapy-outcomes with fixed doses of adrenaline. Nevertheless, repeated doses of adrenaline should be sufficient to alleviate the symptoms in such patients if the weight would be the only reason for the refractoriness of anaphylaxis.

The comparison of refractory anaphylaxis with patients suffering from severe anaphylaxis enabled us to distinguish patients with a higher risk of developing a refractory episode. However, we cannot address the question which patients had a higher risk of experiencing anaphylaxis *per se*.

## CONCLUSION

Refractory anaphylaxis is a rare form of a life-threatening hypersensitivity reaction with high mortality. Its elicitors and cofactors differ from other anaphylaxis cases, and the management of refractory anaphylaxis needs to improve. Although, more studies need to be conducted to understand better the pathomechanisms involved in refractory anaphylaxis, we propose to increase the use of second-line medication such as methylene blue, vasopressin and (in suspicion of a  $\beta$ -adrenergic blockade) glucagon in cases where 2 doses of adrenaline did not result in a rapid normalization of anaphylaxis symptoms.

## DATA AVAILABILITY STATEMENT

All datasets generated for this study are included in the manuscript and/or the supplementary files.

## ETHICS STATEMENT

The ethics commission and data protection officer of the Berlin Charité Hospital approved the study (EA1/079/06). Patients gave their informed consent for the inclusion of their medical information in the registry.

## AUTHOR CONTRIBUTIONS

WF wrote the original manuscript and performed the statistical analysis. SD-B consolidated the data and revised the manuscript critically. MK, KS, EC-J, BG, RL, IM, J-MR, and MW provided data, revised the manuscript critically, and accepted the final version.

## FUNDING

The European Anaphylaxis Registry was supported by the Network for Online-Registration of Anaphylaxis NORA e. V. We acknowledge support from the German Research Foundation

(DFG) and the Open Access Publication Fund of Charité—Universitätsmedizin Berlin.

## ACKNOWLEDGMENTS

We thank all patients, parents, and their children for their support in providing data on the occurrence of anaphylaxis for this study. We thank the study personnel for patients counseling and data entry and we thank the members of The European Anaphylaxis Registry in detail: J. Grünhagen (Berlin, Germany), K. Beyer (Berlin, Germany), A. Möser (Jena, Germany), T. Fuchs (Göttingen, Germany), F. Rüff (Munich, Germany), B. Wedi (Hanover, Germany), F. Friedrichs (Aachen, Germany), H. Dickel (Bochum, Germany), H. Merk (Aachen, Germany), A. Bauer (Dresden, Germany), N. Wagner (Erlangen, Germany), E. Rietschel (Cologne, Germany), R. Treudler, S. Aurich (Leipzig, Germany), L. Klimek, O. Pfaar (Wiesbaden, Germany), N. Reider (Innsbruck, Germany), W. Aberer (Graz, Austria), A. Köhli (Zurich, Switzerland), F. Riffelmann (Schmallenberg, Germany), B. Kreft (Halle, Germany), K. Nemat (Dresden, Germany), T. Kinaciyan (Vienna, Austria), R. Brehler (Münster, Germany), J. Witte (Hamburg, Germany), N. Hunzelmann und I. Huseynow (Cologne, Germany), T. Bieber (Bonn, Germany), U. Rabe (Treuenbritzen, Germany), P. Schmid-Grendelmeier (Zurich, Switzerland), W. Brosi (Würzburg, Germany), S. Nestoris (Lippe-Lemgo, Germany), T. Hawranek (Salzburg, Austria), R. Bruns (Greifswald, Germany), S. Lehmann (Aachen, Germany), L. Lange (Bonn, Germany), G. Hansen (Hanover, Germany), C. Pföhler (Homburg, Germany), E. Varga (Graz, Austria), Z. Szeplafusi (Vienna, Austria), P. Eng (Aarau, Switzerland), P. Eng (Lucerne, Switzerland), T. Reese (Rheine, Germany), M. Polz (Rüsselsheim, Germany), S. Schweitzer-Krantz (Düsseldorf, Germany), H. Rebmann (Tübingen, Germany), G. Stichtenoth (Lübeck, Germany), S. Thies (Schwedt, Germany), I. Yildiz (Neumünster, Germany), M. Gerstlauer (Augsburg, Germany), A. Nordwig (Dresden, Germany), T. Spindler (Wangen im

Allgäu, Germany, now Davos, Switzerland), I. Neustädter (Fürth, Germany), C. Stadlin (Zurich, Switzerland), M. Bücheler (Bonn, Germany), S. Volkmuth (Velbert, Germany), J. Fischer (Tübingen, Germany), A. Henschel (Berlin, Germany), S. Plank-Habibi (Alzenau, Germany), B. Schilling (Passau, Germany), A. Kleinheinz (Buxtehude, Germany), K. Schäkel (Heidelberg, Germany), N. Papadopoulos (Athen, Greece), M. Kowalski (Lodz, Poland), M. Fernandez-Rivas (Madrid, Spain), K. Solarewicz-Madajek (Wroclaw, Poland), C. Körner-Rettberg (Bochum, Germany), T. Mustakov (Sofia, Bulgaria), K. Hartmann (Lübeck, Germany), C. Kemen (Hamburg, Germany), F. Prenzel (Leipzig, Germany), C. Ebner (Vienna, Austria), S. Haak (Oldenburg, Deutschland), V. Cardona (Barcelona, Spain), S. Hämmerling (Heidelberg, Germany), E. Arroabarren (Pamplona, Spain), M. Bilo (Ancona, Italy), N. Cabañes Higuero (Toledo, Spain), A. Vega Castro (Guadalajara, Spain), I. Poziomkowska-Gesicka (Szczecin, Poland), S. Büsing (Osnabrück, Germany), U. Klettke, U. Staden (Berlin, Germany), C. Virchow (Rostock, Germany), G. Christoff (Sofia, Bulgaria), U. Jappe (Borstel, Germany), S. Müller (Freiburg, Germany), H. Straube (Darmstadt, Germany), C. Vogelberg (Dresden, Germany), F. Knöpfel (Norderney, Germany), J. Hourihane (Cork, Ireland), B. Rogala (Silesia, Poland), A. Montoro (Madrid, Spain), A. Brandes (Frankfurt/Oder, Germany), A. Muraro (Padua, Italy), T. Buck und J. Büsselberg (Hanover-Misburg, Germany), N. Zimmermann (Potsdam, Germany), D. Hernandez (Valencia, Spain), P. Minale (Genoa, Italy), J. Niederwimmer und B. Zahel (Linz, Austria), A. Fiocchi (Rome, Italy), A. Reissig (Gera, Germany), F. Horak (Vienna, Austria), S. Meller (Düsseldorf, Germany), F. Eitelberger (Wels, Austria), H. Ott (Hanover, Germany), R. Asero (Milan, Italy), F. Hermann, S. Zeidler (St. Augustin, Deutschland), S. Pistauer (Sylt/Westerland, Germany), M. Geißler (Ribnitz-Damgarten, Germany), L. Ensina (São Paulo, Brazil), A. Plaza Martin (Barcelona, Spain), J. Meister (Aue, Germany), S. Hompes (Hamburg, Germany), S. Stieglitz (Wuppertal, Germany).

## REFERENCES

- Simons FE, Sampson HA. Anaphylaxis: unique aspects of clinical diagnosis and management in infants (birth to age 2 years). *J Allergy Clin Immunol.* (2015) 135:1125–31. doi: 10.1016/j.jaci.2014.09.014
- Grabenhenrich LB, Dölle S, Rüff F, Renaudin JM, Scherer K, Pföhler C, et al. Epinephrine in severe allergic reactions: the european anaphylaxis register. *J Allergy Clin Immunol.* (2018) 6:1898–906. doi: 10.1016/j.jaip.2018.02.026
- Sampson HA, Muñoz-Furlong A, Campbell RL, Adkinson NF, Bock SA, Branum A, et al. Second symposium on the definition and management of anaphylaxis: summary report - Second National Institute of Allergy and Infectious Disease/Food Allergy and Anaphylaxis Network Symposium. *Ann Emerg Med.* (2006) 47:373–80. doi: 10.1016/j.annemergmed.2006.01.018
- Francuzik W, Dölle S, Worm M. Risk factors and treatment of refractory anaphylaxis—a review of case reports. *Expert Rev Clin Immunol.* (2018) 14:307–14. doi: 10.1080/1744666X.2018.1450140
- Grabenhenrich LB, Dölle S, Moneret-Vautrin A, Köhli A, Lange L, Spindler T, et al. Anaphylaxis in children and adolescents: the European anaphylaxis registry. *J Allergy Clin Immunol.* (2016) 137:1128–37.e1. doi: 10.1016/j.jaci.2015.11.015
- Worm M, Francuzik W, Renaudin JM, Bilo MB, Cardona V, Scherer Hofmeier K, et al. Factors increasing the risk for a severe reaction in anaphylaxis: an analysis of data from the European anaphylaxis registry. *Allergy.* (2018) 73:1322–30. doi: 10.1111/all.13380
- R Core Team. *R: A Language and Environment for Statistical Computing.* Vienna: R Foundation for Statistical Computing (2017).
- Muraro A, Roberts G, Worm M, Bilò MB, Brockow K, Fernández Rivas M, et al. Anaphylaxis: guidelines from the European academy of allergy and clinical immunology. *Allergy.* (2014) 69:1026–45. doi: 10.1111/all.12437
- Hepner DL, Castells MC. Anaphylaxis during the perioperative period. *Anesthesia Analgesia.* (2003) 97:1381–95. doi: 10.1213/01.ANE.0000082993.84883.7D
- Ebo DG, Fisher MM, Hagendorens MM, Bridts CH, Stevens WJ. Anaphylaxis during anaesthesia: diagnostic approach. *Allergy.* (2007) 62:471–87. doi: 10.1111/j.1398-9995.2007.01347.x
- McNeil BD, Pundir P, Meeker S, Han L, Undem BJ, Kulka M, et al. Identification of a mast-cell-specific receptor crucial for pseudo-allergic drug reactions. *Nature.* (2015) 519:237–41. doi: 10.1038/nature14022
- Saxon A. Immediate hypersensitivity reactions to  $\beta$ -lactam antibiotics. Reviews of infectious diseases. (1983) 5:S368–79. doi: 10.1093/clindis/5.Supplement\_2.S368



13. Greenberger PA, Patterson R. The prevention of immediate generalized reactions to radioccontrast media in high-risk patients. *J Allergy Clin Immunol.* (1991) 87:867–72. doi: 10.1016/0091-6749(91)90135-B
14. Wang H, Wang HS, Liu ZP. Agents that induce pseudo-allergic reaction. *Drug Discov Ther.* (2011) 5:211–9. doi: 10.5582/ddt.2011.v5.5.211
15. Visscher PK, Vetter RS, Camazine S. Removing bee stings. *Lancet.* (1996) 348:301–2. doi: 10.1016/S0140-6736(96)01367-0
16. Mullins RJ. Anaphylaxis: risk factors for recurrence. *Clin Exp Allergy.* (2003) 33:1033–40. doi: 10.1046/j.1365-2222.2003.01671.x
17. Klion AD, Noel P, Akin C, Law MA, Gilliland DG, Cools J, et al. Elevated serum tryptase levels identify a subset of patients with a myeloproliferative variant of idiopathic hypereosinophilic syndrome associated with tissue fibrosis, poor prognosis, and imatinib responsiveness. *Blood.* (2003) 101:4660–6. doi: 10.1182/blood-2003-01-0006
18. Caughey GH. Tryptase genetics and anaphylaxis. *J Allergy Clin Immunol.* (2006) 117:1411–4. doi: 10.1016/j.jaci.2006.02.026
19. Lyons JJ. Hereditary alpha tryptasemia. *Immunol Allergy Clin North Am.* (2018) 38:483–95. doi: 10.1016/j.iac.2018.04.003
20. Aniceto V, Dias MM, Melo JML, Trevisan-Neto O, Aragon DC, Maia LSM, et al. Serum baseline tryptase level as a marker for the severity of anaphylaxis. *Int Arch Allergy Immunol.* (2019) 179:201–8. doi: 10.1159/000497235
21. Lee C, Gianos M, Klaustermeyer WB. Diagnosis and management of hypersensitivity reactions related to common cancer chemotherapy agents. *Ann Allergy Asthma Immunol.* (2009) 102:179–87. doi: 10.1016/S1081-1206(10)60078-6
22. Burns VE, Edwards KM, Ring C, Drayson M, Carroll D. Complement cascade activation after an acute psychological stress task. *Psychosom Med.* (2008) 70:387–96. doi: 10.1097/PSY.0b013e31816ded22
23. Arck PC, Handjiski B, Peters EM, Peter AS, Hagen E, Fischer A, et al. Stress inhibits hair growth in mice by induction of premature catagen development and deleterious perifollicular inflammatory events via neuropeptide substance p-dependent pathways. *Am J Pathol.* (2003) 162:803–14. doi: 10.1016/S0002-9440(10)63877-1
24. Bossaller C, Reither K, Hehlert-Friedrich C, Auch-Schwelk W, Graf K, Gräfe M, et al. *In vivo* measurement of endothelium-dependent vasodilation with substance p in man. *Herz.* (1992) 17:284–90.
25. Singh LK, Pang X, Alexacos N, Letourneau R, Theoharides TC. Acute immobilization stress triggers skin mast cell degranulation via corticotropin releasing hormone, neurotensin, and substance p: a link to neurogenic skin disorders. *Brain Behav Immun.* (1999) 13:225–39. doi: 10.1006/brbi.1998.0541
26. Alevizos M, Karagkouni A, Kontou-Fili K, Theoharides TC. A probable case report of stress-induced anaphylaxis. *Ann Allergy Asthma Immunol.* (2014) 112:383–4. doi: 10.1016/j.anai.2013.07.018
27. Wölbing F, Fischer J, Köberle M, Kaesler S, Biedermann T. About the role and underlying mechanisms of cofactors in anaphylaxis. *Allergy.* (2013) 68:1085–92. doi: 10.1111/all.12193
28. Natsch S, Vinks MH, Voogt AK, Mees EB, Meyboom RH. Anaphylactic reactions to proton-pump inhibitors. *Ann Pharmacother.* (2000) 34:474–6. doi: 10.1345/aph.19235
29. Faria E, Rodrigues-Cernadas J, Gaspar A, Botelho C, Castro E, Lopes A, et al. Drug-induced anaphylaxis survey in portuguese allergy departments. (2014) 24:40–8.
30. Fleg JL, O'Connor F, Gerstenblith G, Becker LC, Clulow J, Schulman SP, et al. Impact of age on the cardiovascular response to dynamic upright exercise in healthy men and women. *J Appl Physiol.* (1995) 78:890–900. doi: 10.1152/jappl.1995.78.3.890
31. Rogers KM, McCutcheon K. Understanding arterial blood gases. *J Perioperat Pract.* (2013) 23:191–7. doi: 10.1177/175045891302300903
32. Tanida M, Zhang T, Sun L, Song J, Yang W, Kuda Y, et al. Anaphylactic hypotension causes renal and adrenal sympathoexcitation and induces c-fos in the hypothalamus and medulla oblongata. *Exp Physiol.* (2018) 103:790–806. doi: 10.1113/EP086809
33. Song TT, Brown D, Karjalainen M, Lehnigk U, Lieberman P. Value of a second dose of epinephrine during anaphylaxis: a patient/caregiver survey. *J Allergy Clin Immunol.* (2018) 6:1559–67. doi: 10.1016/j.jaip.2018.01.019
34. Evora PRB. Should methylene blue be the drug of choice to treat vasoplegias caused by cardiopulmonary bypass and anaphylactic shock? *J Thorac Cardiovasc Surg.* (2000) 119:632–3. doi: 10.1016/S0022-5223(00)70152-8
35. Dfaz JE, Roberts JR. Anaphylactic shock. *Schweiz Rundsch Med Prax.* (1995) 84:1307–13.
36. Tucker D, Lu Y, Zhang Q. From mitochondrial function to neuroprotection—an emerging role for methylene blue. *Mol Neurobiol.* (2017) 55:5137–53. doi: 10.1007/s12035-017-0712-2
37. Simons FE, Arduoso LR, Bilò MB, El-Gamal YM, Ledford DK, Ring J, et al. World allergy organization guidelines for the assessment and management of anaphylaxis. *World Allergy Organ J.* (2011) 4:13–36. doi: 10.1097/WOX.0b013e318211496c
38. Lieberman P, Kemp S, Oppenheimer J, Lang DM, Bernstein IL, Nicklas RA, et al. The diagnosis and management of anaphylaxis: an updated practice parameter. *J Allergy Clin Immunol.* (2005) 115:S483–523. doi: 10.1016/j.jaci.2005.01.010
39. Harper NJN, Cook TM, Garcez T, Lucas DN, Thomas M, Kemp H, et al. Anaesthesia, surgery, and life-threatening allergic reactions: management and outcomes in the 6th national audit project (nap6). *Br J Anaesth.* (2018) 12:172–88. doi: 10.1016/j.bja.2018.04.015
40. Zaloga GP, DeLacey W, Holmboe E, Chernow B. Glucagon reversal of hypotension in a case of anaphylactoid shock. *Ann Intern Med.* (1986) 105:65–6. doi: 10.7326/0003-4819-105-1-65
41. Javed N, Javed H, Javed S, Moussa G, Wong P, Rezai F. Refractory anaphylactoid shock potentiated by beta-blockers. *Cathet Cardiovasc Diagn.* (1996) 39:383–4. doi: 10.1002/(SICI)1097-0304(199612)39:4<383::AID-CCD13>3.3.CO;2-G

**Conflict of Interest:** The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2019 Francuzik, Dölle-Bierke, Knop, Scherer Hofmeier, Cichocka-Jarosz, García, Lang, Maris, Renaudin and Worm. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.